ADP Diagnostics is an innovative diagnostics company based in Carrickfergus, Northern Ireland, supplying products to the Clinical Diagnostic Laboratories in both the public and private sectors.
As a science graduate of Ulster University and now with 25 years experience in clinical diagnostics, my goal for ADP Diagnostics is to make it a world leader in supplying speciality quality controls, Drugs of Abuse testing kits and POCT equipment. We work with carefully chosen manufacturers and strive to provide bespoke solutions for our customers. Research & Development, validations and trials are carried out in our own laboratory. The excellent laboratories in our local Belfast hospitals also provide invaluable validation data for our clinical products.
ADP Diagnostics is an ISO 9001:2015 registered company, recognising the quality of our administrative and management systems.
Greg Simpson Bsc.
Managing Director
| TOX-SCREEN 14 PANEL DRUG TEST SYSTEM | ||
| UCP-100 DRUG CUP SYSTEM |
|
Sample collection urine cup Unique 14 Panel 10 minutes to test results Accurate, Precise, Reproducible results On board quality control |
| DIP-CARD URINE TEST |
|
Rapid Test Dip-card Unique 14 Panel Fast. Test results in 10 minutes Easy. 3 step operation Minimal training required |
| UNIQUE 14 PANEL | AMP, BAR, BZO, COC, EDDP, FEN, K2, KET, THC, mAMP, MDMA, OPI, TRA, TCA | MHRA REGISTERED |
| FAST AND RELIABLE | SIMPLE SAMPLE PROTOCOL | AVAILABLE NOW |
04 March 2021
R&D is the central focus of our company, coming up with new products that solve gaps in diagnostic testing and quality control on behalf of our customers. This is how ADP developed the world's first Serum Indices Quality Control sera which combines Haemolysis, Icterus & Lipaemia in a single control.
Every day in hospital laboratories across the world, millions of patient samples are being scanned on automated analysers for compromised samples. The ‘flag’ rate for compromised samples from Serum Indices (Haemolysis, Icterus, Lipaemia) can be up to 10%. However, how do we know that the automated analysers are accurately scanning the samples for Serum Indices?
Our Serum Indices QC is the only 3rd party QC sera available on the market and is essential for any laboratory that needs to comply with national and international standards, such as ISO 15189 accreditation. The product is currently being used by hospital laboratories throughout the UK and Ireland, Europe and Australia.
**Instrument specific controls are available for Beckman, Roche, Siemens and Abbott analysers**
Contact us on 028 9336 6929 for more information.
19 February 2021
An important indicator of ovarian reserve is a blood test called Anti Mullerian Hormone. It is a very sensitive marker of ovarian reserve used by fertility clinics, with the analysis performed in the Clinical Laboratory.
The ADP Tri-Level anti-Mullerian Hormone (MIS) Quality Control set is designed to monitor the performance of AMH immunoassays. This quality control has been validated against the Roche (ECLIA) immunoassay on the Roche Cobas analysers. This is a new product that enables clinicians to have a 3rd party QC for their laboratories.
The quality control has been developed in conjunction with the Royal Victoria Hospital in Belfast, Northern Ireland. The levels have been chosen to reflect critical clinical cut-off values around 12 pmol/L, a mid assay and an elevated level of 47 pmol/L, to check the linearity of the assay.
Stored frozen, defrosted it is stable for 7 days. The kit contains 2 bottles of each level, 3 levels, and 2 mls per vial ( 2 x 3 x 2ml).
Contact ADP Diagnostics for further information or for more information on our range of niche quality controls click here.
Further references:
References: Clinical Biochemistry Volume 49, Issue 3, February 2016, Pages 260–267
(The 2013 National Institute for Health and Care Excellence (NICE) clinical guideline for fertility and the European Society of HumanReproduction and Embryology (ESHRE) recommend AMH measurement as one method to predict ovarian response to gonadotropin stimulation [12] and [13]. The NICE guideline states that AMH concentration of ≤ 0.75 ng/ml (≤ 5.4 pmol/L) indicates a low ovarian response to stimulation, whereas AMH concentration ≥3.50 ng/ml (≥ 25.0 pmol/L) indicates a high response [12]. It follows that precise and accurate AMH measurement in these intervals is a prerequisite for reliable interpretation of AMH results in a clinical setting)
